Rifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple indications and is used in treatment of traveller's diarrhea caused by E. coli; reduction in risk of overt hepatic encephalopathy recurrence; as well as diarrhea-predominant irritable bowel syndrome (IBS-D) in adult women and men. It is marketed under the brand name Xifaxan by Salix Pharmaceuticals.
Rifaximin has multiple indications by the FDA: for the treatment of patients (≥12 years of age) with traveller's diarrhea caused by noninvasive strains of Escherichia coli; for the reduction of overt hepatic encephalopathy recurrence in patients ≥18 years of age; and in May 2015 it was approved for irritable bowel syndrome with diarrhea (IBS-D) treatment in adult men and women.
Westchester Medical Cancer Cancer Institute, Valhalla, New York, United States
Global Clinical Professionals, Saint Petersburg, Florida, United States
Inland Empire Clinical Trials, Rialto, California, United States
Southern California Research Center, Coronado, California, United States
180 Fenglin Road, Shanghai, Shanghai, China
University of California San Francisco, San Francisco, California, United States
Children's Healthcare of Atlanta, Atlanta, Georgia, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
The Sixth Affiliated Hospital, Sun Yat-sen University, Guanzhou, Guangdong, China
The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Hospital Universitario de La Princesa, Madrid, Spain
Institute of Liver and Biliary Sciences, New Delhi, Delhi, India
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.